View Older Stories View More Recent Stories

Jan 20, 2026 07:30AM Dyne Therapeutics receives orphan drug designation in Japan for DM1 treatment
Dec 10, 2025 06:54AM Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform
Dec 9, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $23 at Bernstein SocGen Group
Dec 8, 2025 04:57PM After-hours movers: NVIDIA, Toll Brothers, and more
Dec 8, 2025 12:06PM Dyne Therapeutics (DYN) PT Raised to $50 at Morgan Stanley
Dec 8, 2025 09:27AM Dyne Therapeutics (DYN) PT Raised to $60 at H.C. Wainwright
Dec 8, 2025 09:26AM Baird Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Dec 8, 2025 07:40AM Dyne Therapeutics (DYN) PT Raised to $40 at Raymond James
Nov 27, 2025 02:00AM Bernstein sees favorable risk-reward in this biotech stock
Nov 25, 2025 07:30AM Dyne Therapeutics (DYN) PT Raised to $21 at Bernstein SocGen Group, we see risk-reward as favorable
Nov 16, 2025 03:00PM Where can biotech stocks go from here? RBC answers
Nov 5, 2025 05:56PM Dynegy (DYN) Tops Q3 EPS by 8c
Oct 24, 2025 08:29AM Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
Oct 10, 2025 06:04AM Oppenheimer Downgrades Dyne Therapeutics (DYN) to Perform
Sep 29, 2025 08:35AM Dyne Therapeutics gets orphan drug status in Japan for DMD therapy
Sep 29, 2025 07:57AM Piper Sandler: 'Own Dyne Therapeutics (DYN) for DELIVER Data in Late 2025'
Sep 11, 2025 08:18AM RBC Capital on Biotech Shares: 'Company-Specific Volatility For Quality Names May Be Overdone'
Aug 25, 2025 06:05AM Raymond James Upgrades Dyne Therapeutics (DYN) to Strong Buy
Aug 6, 2025 11:20AM Dyne Therapeutics Inc. (DYN) gains following Avidity Biosciences Inc. (RNA) Takeover Rumors, Up 24%
Aug 4, 2025 08:31AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
Jul 30, 2025 04:40PM Dyne Therapeutics (DYN) PT Lowered to $36 at Stifel
Jul 28, 2025 04:40PM Dynegy (DYN) Misses Q2 EPS by 3c
Jul 2, 2025 07:41AM Dyne Therapeutics (DYN) PT Lowered to $11.50 at Bernstein
Jun 30, 2025 04:05PM Dyne Therapeutics Inc. (DYN) Announces Proposed $200M Share Offering
Jun 30, 2025 04:02PM Dyne Therapeutics (DYN) Secures Up to $275 Million in Debt Financing from Hercules Capital
Jun 25, 2025 04:12PM Jones Trading Starts Dyne Therapeutics (DYN) at Buy
Jun 18, 2025 06:43AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
Jun 17, 2025 09:39AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN) Following FDA Update
Jun 17, 2025 07:01AM Dyne Therapeutics (DYN) Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting
Jun 5, 2025 12:44PM FDA Cell and Gene Therapy Roundtable 'bullish for the space' - Stifel
Jun 2, 2025 08:52AM Oppenheimer Assumes Dyne Therapeutics (DYN) at Outperform (correction)
May 29, 2025 06:15AM Evercore ISI Starts Dyne Therapeutics (DYN) at Outperform
May 13, 2025 02:22PM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN), PT $66
May 12, 2025 06:57AM Dyne Therapeutics (DYN) PT Lowered to $38 at H.C. Wainwright
May 8, 2025 05:27PM Dynegy (DYN) Misses Q1 EPS by 20c
Apr 24, 2025 07:32AM Dyne Therapeutics Inc. (DYN) Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy
Apr 15, 2025 07:31AM Dyne Therapeutics Inc. (DYN) Announces Chief Business Officer and Chief Scientific Officer Appointments
Mar 26, 2025 05:58AM BMO Capital Reiterates Outperform Rating on Dyne Therapeutics (DYN)
Mar 20, 2025 04:25PM Dyne Therapeutics (DYN) PT Lowered to $17 at JPMorgan
Mar 20, 2025 04:11PM Dyne Therapeutics (DYN) Announces Appointment of Erick J. Lucera as Chief Financial Officer
Mar 17, 2025 09:39AM H.C. Wainwright Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 17, 2025 08:08AM Piper Sandler Reiterates Overweight on Dyne Therapeutics (DYN) as 'DYNE-251 Continues to DELIVER'
Mar 17, 2025 07:56AM Stifel Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 17, 2025 07:53AM Chardan Capital Markets Reiterates Buy Rating on Dyne Therapeutics (DYN)
Mar 11, 2025 04:11PM BMO Capital Starts Dyne Therapeutics (DYN) at Outperform
Mar 7, 2025 07:08AM Scotiabank Starts Dyne Therapeutics (DYN) at Sector Outperform
Feb 28, 2025 07:14AM Dyne Therapeutics (DYN) PT Lowered to $46 at H.C. Wainwright
Feb 28, 2025 06:47AM Dyne Therapeutics (DYN) PT Lowered to $48 at Piper Sandler
Jan 21, 2025 11:51AM Oppenheimer Reiterates Outperform Rating on Dyne Therapeutics (DYN), PT $60
Jan 21, 2025 07:30AM Dyne Therapeutics (DYN) Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
View More Recent Stories View Older Stories